Get the Stockscreener App
25.50
1.88%
0.47
Beam Therapeutics Inc stock is traded at $25.50, with a volume of 832.60K.
It is up +1.88% in the last 24 hours and down -3.52% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$25.03
Open:
$25.11
24h Volume:
832.60K
Relative Volume:
0.32
Market Cap:
$2.59B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-14.09
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+14.81%
1M Performance:
-3.52%
6M Performance:
+51.07%
1Y Performance:
-6.25%
1-Day Range:
$24.57
$25.55
1-Week Range:
$22.30
$25.55
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
25.50 | 2.54B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.09 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
910.34 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - sharewise.com
Is Beam Therapeutics Inc. stock a defensive play in 20252025 Winners & Losers & Free Technical Pattern Based Buy Signals - BỘ NỘI VỤ
(BEAM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Evercore ISI Group Initiates Coverage of Beam Therapeutics (BEAM) with Outperform Recommendation - Nasdaq
Beam Therapeutics (BEAM) Receives New 'Outperform' Rating from E - GuruFocus
How Beam Therapeutics Inc. stock valuations compare to rivals - newser.com
Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
Is Beam Therapeutics Inc. stock supported by innovation pipeline2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
How Beam Therapeutics Inc. stock compares to market leaders2025 Biggest Moves & AI Powered Buy/Sell Recommendations - newser.com
Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward - MSN
Historical volatility pattern of Beam Therapeutics Inc. visualized2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Why retail investors favor Beam Therapeutics Inc. stockJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
Real time social sentiment graph for Beam Therapeutics Inc.Market Risk Report & Low Volatility Stock Recommendations - newser.com
9 Best Gene-Editing Stocks to Buy According to Hedge Funds - Insider Monkey
BEAM Therapeutics’ SWOT analysis: genetic medicine stock faces pivotal year ahead - Investing.com Canada
Visualizing Beam Therapeutics Inc. stock with heatmapsOil Prices & Precise Buy Zone Identification - newser.com
Published on: 2025-11-16 06:02:52 - newser.com
(BEAM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
What hedge fund activity signals for Beam Therapeutics Inc. stockJuly 2025 Snapshot & Reliable Intraday Trade Alerts - newser.com
How buybacks impact Beam Therapeutics Inc. stock value2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
Why Beam Therapeutics Inc. stock is favored by pension fundsPortfolio Value Summary & High Conviction Investment Ideas - newser.com
Beam Therapeutics (BEAM): Exploring Valuation as Clinical Milestones Revitalize Investor Interest - Yahoo Finance
Will Beam Therapeutics Inc. stock deliver long term returnsPortfolio Growth Summary & Consistent Return Investment Signals - newser.com
How to monitor Beam Therapeutics Inc. with trend dashboards2025 Buyback Activity & Weekly Stock Breakout Alerts - newser.com
Institutional scanner results for Beam Therapeutics Inc.Market Growth Review & Community Consensus Trade Signals - newser.com
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - The Globe and Mail
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Oct 01 '25 |
Sale |
24.53 |
467 |
11,456 |
44,045 |
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
0.45%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):